Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15380MR)

This product GTTS-WQ15380MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15380MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13224MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ10480MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ7736MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ11232MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ12122MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ9805MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ6001MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW